Congrats to MT and the PAA team for seeing MPL though to phase 2/3 trial.
HEALEY was on the cards prior to MT's departure, and I'm sure the impact running the trial through HEALEY would have been a big reason for his return.
MPL will be in front of a global audience now, and if it can replicate the Phase 1 results, then PAA will be a global leader in neurological treatments.
GLTAH DYOR!
Ann: Monepantel Selected for Entry into HEALEY ALS Platform Trial, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $86.15M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.5¢ | 16.5¢ | $91.76K | 527.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 80407 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 31 | 1 |
View Market Depth
| Last trade - 15.34pm 20/06/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |